ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Earnings Estimates
NASDAQ:RARE • US90400D1081
20.45 USD
+0.27 (+1.34%)
At close: Feb 18, 2026
20.45 USD
0 (0%)
After Hours: 2/18/2026, 4:30:02 PM
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 434.249M 19.53% | 560.23M 29.01% | 673M 20.13% | 788.98M 17.23% | 1.074B 36.13% | 1.335B 24.30% | 1.95B 46.07% | 2.539B 30.21% | 2.526B -0.51% | 2.975B 17.78% | 3.574B 20.13% | |
| EBITDA YoY % growth | -543.202M 13.87% | -500.43M 7.87% | N/A -1.42% | -335.002M 34.00% | -74.197M 77.85% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -569.208M 12.28% | -535.973M 5.84% | -535M 0.18% | -382.316M 28.54% | -121.732M 68.16% | 241.53M 298.41% | 527.05M 118.21% | 946.92M 79.66% | 1.052B 11.10% | 1.316B 25.10% | 1.776B 34.95% | |
| Operating Margin | -131.08% | -95.67% | -79.49% | -48.46% | -11.33% | 18.09% | 27.03% | 37.29% | 41.65% | 44.24% | 49.69% | |
| EPS YoY % growth | -8.33 17.61% | -6.34 23.89% | -5.84 7.89% | -3.96 32.24% | -1.39 64.80% | 1.68 220.53% | 4.95 194.78% | 8.93 80.34% | 9.76 9.31% | 12.55 28.66% | 12.64 0.73% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.62 -3.23% | -1.20 -2.27% | -1.11 38.52% | -0.73 43.57% | -0.94 42.10% | -0.23 80.39% | 0.06 105.50% | 0.67 192.48% |
| Revenue Q2Q % growth | 173.14M 24.30% | 190.49M 14.41% | 200.23M 25.20% | 234.81M 13.43% | 213.48M 23.30% | 278.32M 46.11% | 311.54M 55.59% | 389.47M 65.87% |
| EBITDA Q2Q % growth | -108.331M 19.12% | -95.827M -6.15% | -94.626M 34.59% | -101.325M 6.00% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -129.634M 9.31% | -110.753M -2.66% | -104.008M 39.14% | -95.236M 16.46% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2025 Q2Q % growth | -1.29 7.19% | -1.11 | -0.18 | -15.82% |
| Q3 2025 Q2Q % growth | -1.81 -29.29% | -1.26 | -0.55 | -43.75% |
| Q2 2025 Q2Q % growth | -1.17 23.03% | -1.32 | 0.15 | 11.68% |
| Q1 2025 Q2Q % growth | -1.57 22.66% | -1.65 | 0.08 | 4.60% |
| Q4 2024 Q2Q % growth | -1.39 8.55% | -1.32 | -0.07 | -5.63% |
| Q3 2024 Q2Q % growth | -1.40 37.22% | -1.48 | 0.08 | 5.37% |
| Q2 2024 Q2Q % growth | -1.52 32.44% | -1.73 | 0.21 | 12.01% |
| Q1 2024 Q2Q % growth | -2.03 12.88% | -1.77 | -0.26 | -14.94% |
| Q4 2023 Q2Q % growth | -1.52 29.63% | -1.65 | 0.13 | 7.99% |
| Q3 2023 Q2Q % growth | -2.23 36.29% | -2.12 | -0.11 | -5.20% |
| Q2 2023 Q2Q % growth | -2.25 0.44% | -2.12 | -0.13 | -6.35% |
| Q1 2023 Q2Q % growth | -2.33 -6.39% | -2.02 | -0.31 | -15.58% |
| Q4 2022 Q2Q % growth | -2.16 -20.67% | -2.18 | 0.02 | 1.14% |
| Q3 2022 Q2Q % growth | -3.50 -224.07% | -1.85 | -1.65 | -89.21% |
| Q2 2022 Q2Q % growth | -2.26 -24.86% | -1.79 | -0.47 | -26.47% |
| Q1 2022 Q2Q % growth | -2.19 -7.88% | -1.80 | -0.39 | -21.97% |
| Q4 2021 Q2Q % growth | -1.79 -383.78% | -1.37 | -0.42 | -30.74% |
| Q3 2021 Q2Q % growth | -1.08 4.42% | -1.44 | 0.36 | 24.80% |
| Q2 2021 Q2Q % growth | -1.81 -541.46% | -1.36 | -0.45 | -33.07% |
| Q1 2021 Q2Q % growth | -2.03 -6.28% | -1.26 | -0.77 | -60.89% |
| Q4 2020 Q2Q % growth | -0.37 | -1.18 | 0.81 | 68.76% |
| Q3 2020 Q2Q % growth | -1.13 | -1.28 | 0.15 | 11.98% |
| Q2 2020 Q2Q % growth | 0.41 | -1.57 | 1.98 | 126.03% |
| Q1 2020 Q2Q % growth | -1.91 | -1.72 | -0.19 | -11.34% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2025 Q2Q % growth | 207M 25.55% | 200.91M | 6.09M | 3.03% |
| Q3 2025 Q2Q % growth | 159.933M 14.65% | 170.04M | -10.107M | -5.94% |
| Q2 2025 Q2Q % growth | 166.496M 13.24% | 164.82M | 1.676M | 1.02% |
| Q1 2025 Q2Q % growth | 139.292M 27.99% | 146.7M | -7.408M | -5.05% |
| Q4 2024 Q2Q % growth | 164.877M 29.42% | 158.5M | 6.377M | 4.02% |
| Q3 2024 Q2Q % growth | 139.494M 42.27% | 138.51M | 984K | 0.71% |
| Q2 2024 Q2Q % growth | 147.026M 35.75% | 125.64M | 21.386M | 17.02% |
| Q1 2024 Q2Q % growth | 108.833M 8.30% | 118.33M | -9.497M | -8.03% |
| Q4 2023 Q2Q % growth | 127.392M 23.32% | 121.77M | 5.622M | 4.62% |
| Q3 2023 Q2Q % growth | 98.052M 8.11% | 111.82M | -13.768M | -12.31% |
| Q2 2023 Q2Q % growth | 108.309M 21.29% | 106.9M | 1.409M | 1.32% |
| Q1 2023 Q2Q % growth | 100.496M 25.78% | 106.78M | -6.284M | -5.88% |
| Q4 2022 Q2Q % growth | 103.3M 23.86% | 107.22M | -3.92M | -3.66% |
| Q3 2022 Q2Q % growth | 90.7M 11.15% | 98.121M | -7.421M | -7.56% |
| Q2 2022 Q2Q % growth | 89.3M 2.64% | 89.265M | 35K | 0.04% |
| Q1 2022 Q2Q % growth | 79.9M -19.62% | 85.327M | -5.427M | -6.36% |
| Q4 2021 Q2Q % growth | 83.4M -8.85% | 85.471M | -2.071M | -2.42% |
| Q3 2021 Q2Q % growth | 81.6M 0.12% | 83.178M | -1.578M | -1.90% |
| Q2 2021 Q2Q % growth | 87M 41.00% | 87.6M | -600K | -0.68% |
| Q1 2021 Q2Q % growth | 99.4M 173.83% | 78.58M | 20.82M | 26.50% |
| Q4 2020 Q2Q % growth | 91.5M | 71.955M | 19.545M | 27.16% |
| Q3 2020 Q2Q % growth | 81.5M | 56.107M | 25.393M | 45.26% |
| Q2 2020 Q2Q % growth | 61.7M | 39.901M | 21.799M | 54.63% |
| Q1 2020 Q2Q % growth | 36.3M | 37.477M | -1.177M | -3.14% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 3.73% | 7.93% | 2.75% | -10.85% |
| Revenue | 2.77% | 5.76% | 0.58% | 0.61% |